Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer.
OBJECTIVE
To evaluate the anti-glycolytic effects of 3-BrPA on rats bearing RMT mammary tumors, by determining FDG uptake after intravenous administration of the therapeutic dose.


METHODS
Sixteen rats bearing RMT tumors were treated either with 15 mM 3-BrPA in 2.5 ml of PBS or with 2.5 ml of PBS. After treatment, all rats received FDG and were sacrificed 1 h later.


RESULTS
3-BrPA treatment significantly decreased FDG uptake in tumors by 77% (p = 0.002). FDG uptake did not significantly decrease in normal tissues after treatment.


CONCLUSIONS
Our study showed that 3-BrPA exhibits a strong anti-glycolytic effect on RMT cells implanted in rats.
Russell H. Morgan Department of Radiology, and Radiological Sciences, Division of Vascular and Interventional Radiology, 600 North Wolfe Street, Blalock 545, Baltimore, MD 21287, USA.
Manon
M
Buijs
Josephina A
JA
Vossen
Jean-Francois H
JF
Geschwind
Takayoshi
T
Ishimori
James M
JM
Engles
Obele
O
Acha-Ngwodo
Richard L
RL
Wahl
Mustafa
M
Vali
D000818:Animals; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism*; D006019:Glycolysis / Q000187:drug effects*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism; D011773:Pyruvates / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011917:Rats, Inbred Lew
D011773:Pyruvates; D019788:Fluorodeoxyglucose F18; C017092:bromopyruvate